logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
R

Rina Hui

the university of sydney
H指数:63
被引数:4.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical Characteristics and Surgical Outcomes of Patients Receiving Perioperative Pembrolizumab in KEYNOTE-671

接受围手术期帕博利珠单抗治疗患者的临床特征与手术结局——KEYNOTE-671研究

The Annals of Thoracic Surgery
IF0
2025-11-050
PRE
Moishe Liberman; David R. Jones; Heather Wakelee; Shugeng Gao; Balazs Halmos; Ernest Nadal; Anna Łowczak; Martin Reck; Silvia Novello; Danielli Matias; Alexander Luft; Rina Hui; Se-Hoon Lee; Masahiro Tsuboi; Terufumi Kato; Yuming Zhu; Benny Weksler; Erin Jensen; Ayman Samkari; Steven M. Keller; Jonathan D. Spicer
Molecular Tumor Boards: A consensus statement from the International Association for the Study of Lung Cancer

分子肿瘤委员会：国际肺癌研究协会的共识声明

Journal of Thoracic Oncology
IF20.8
2025-07-070
PRE
Mihaela Aldea; Julia K. Rotow; Maria Arcila; Matthew Hatton; Lynette Sholl; Christian Rolfo; Marco Tagliamento; Teodora Radonic; Kurt A. Schalper; Vivek Subbiah; Umberto Malapelle; Anja C. Roden; Rami Manochakian; Ming-Sound Tsao; Helena Linardou; Rina Hui; Silvia Novello; Alastair Greystoke; Anjali Saqi; Sylvie Lantuejoul; David M. Hwang; Kelly Nevins; Murry Wynes; Saiama Waqar; Yuchen Han; Yasushi Yatabe; Wei-Chin Chang; Takuo Hayashi; Tae-Jung Kim; Paul Hofman; Fabio Tavora; Fred R. Hirsch; Valeria Denninghoff; Natasha B. Leighl; Alexander Drilon; Wendy A. Cooper; Sanja Dacic; Pranshu Mohindra; Nick Pavlakis; Fernando Lopez-Rios
LEAP-008: Lenvatinib Plus Pembrolizumab for Metastatic NSCLC That Has Progressed After an Anti–PD-(L)1 Plus Platinum Chemotherapy

LEAP-008: Lenvatinib联合Pembrolizumab治疗既往接受过抗PD-(L)1联合铂类化疗后进展的转移性NSCLC

Journal of Thoracic Oncology
IF20.8
2025-06-030
PREAI
Natasha B. Leighl; Luis Paz-Ares; Delvys Rodriguez Abreu; Rina Hui; Sofia Baka; Frédéric Bigot; Makoto Nishio; Alexey Smolin; Samreen Ahmed; Adam J. Schoenfeld; Sameh Daher; Diego L. Cortinovis; Vincenzo Di Noia; Helena Linardou; Justin F. Gainor; Corina Dutcus; Chinyere E. Okpara; Xuan Deng; Debra Kush; Ashwini Arunachalam; Andrew Song; Byoung Chul Cho
Lenvatinib Plus Pembrolizumab, Pemetrexed, and a Platinum as First-Line Therapy for Metastatic Nonsquamous Non–Small-Cell Lung Cancer: Phase 3 LEAP-006 Study

仑伐替尼联合帕博利珠单抗、培美曲塞和铂类药物作为转移性非鳞状非小细胞肺癌的一线治疗方案：III期LEAP-006研究

Journal of Thoracic Oncology
IF20.8
2025-05-240
PREAI
Roy S. Herbst; Byoung Chul Cho; Caicun Zhou; Mauricio Burotto; Manuel Cobo Dols; Mehmet A.N. Sendur; Vladimir Moiseyenko; Ignacio Casarini; Makoto Nishio; Rina Hui; Elvire Pons-Tostivint; Julia Dudnik; Samreen Ahmed; Chinyere E. Okpara; Corina Dutcus; Lina Yin; Yiwen Luo; Diana Chirovsky; Niyati Bhagwati; Delvys Rodriguez Abreu
A phase III, randomized study of adjuvant sacituzumab tirumotecan (sac-TMT) plus pembrolizumab vs treatment of physician's choice (TPC) in patients with TNBC who received neoadjuvant therapy and did not achieve a pathological complete response (pCR) at surgery

一项关于辅助治疗中sacituzumab tirumotecan（sac-TMT）联合pembrolizumab与医生选择治疗方案（TPC）对比的III期随机研究，研究对象为接受新辅助治疗且手术中未达到病理完全缓解（pCR）的TNBC患者。

ANNALS OF ONCOLOGY
IF65.4
2024-12-010
PRE
Dent, R. A.; Hui, R.; Park, Y. H.; Schmid, P.; Wei, J.; Mejia, J. A.; Pan, W.; Cortes, J.; McArthur, H. L.
Neoadjuvant pembrolizumab plus chemotherapy/adjuvant pembrolizumab for early-stage triple-negative breast cancer: quality-of-life results from the randomized KEYNOTE-522 study
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
IF7.2
2024-06-243
OAAI
Dent, Rebecca; Cortes, Javier; Pusztai, Lajos; McArthur, Heather; Kuemmel, Sherko; Bergh, Jonas; Denkert, Carsten; Park, Yeon Hee; Hui, Rina; Harbeck, Nadia; Takahashi, Masato; Untch, Michael; Fasching, Peter A.; Cardoso, Fatima; Haiderali, Amin; Jia, Liyi; Nguyen, Allison Martin; Pan, Wilbur; O'Shaughnessy, Joyce; Schmid, Peter
Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage triple-negative breast cancer: Updated event-free survival results from the phase 3 KEYNOTE-522 study
CANCER RESEARCH
IF16.6
2024-05-020
PRE
Schmid, Peter; Cortes, Javier; Dent, Rebecca; Pusztai, Lajos; McArthur, Heather; Kuemmel, Sherko; Denkert, Carsten; Park, Yeon Hee; Hui, Rina; Harbeck, Nadia; Takahashi, Masato; Foukakis, Theodoros; Mouret-Reynier, Marie-Ange; Ferreira, Marta; Im, Seock-Ah; Cardoso, Fatima; Ding, Yu; Pan, Wilbur; Tryfonidis, Konstantinos; O'Shaughnessy, Joyce
Safety evaluation from the KEYNOTE-522 study of neoadjuvant pembrolizumab (or placebo) plus chemotherapy followed by adjuvant pembrolizumab (or placebo) in patients with early triple-negative breast cancer (TNBC)
CANCER RESEARCH
IF16.6
2024-05-020
PRE
Cortes, Javier; Dent, Rebecca; Pusztai, Lajos; McArthur, Heather; Kuemmel, Sherko; Denkert, Carsten; Park, Yeon Hee; Hui, Rina; Takahashi, Masato; Barrios, Carlos; Zhu, Yalin; Zhang, Xiaoli; Pan, Wilbur; Karantza, Vassiliki; O'Shaughnessy, Joyce; Schmid, Peter
Phase 3 study of neoadjuvant pembrolizumab or placebo plus chemotherapy, followed by adjuvant pembrolizumab or placebo plus endocrine therapy for early-stage high-risk ER+/ HER2-breast cancer: KEYNOTE-756
CANCER RESEARCH
IF16.6
2024-05-026
PRE
Cardoso, Fatima; O'Shaughnessy, Joyce; McArthur, Heather; Schmid, Peter; Cortes, Javier; Harbeck, Nadia; Telli, Melinda; Cescon, David; Fasching, Peter A.; Shao, Zhimin; Loirat, Delphine; Park, Yeon Hee; Fernandez, Manuel Gonzalez; Rubovszky, Gabor; Im, Seock-Ah; Hui, Rina; Takano, Toshimi; Andre, Fabrice; Yasojima, Hiroyuki; Liu, Zhenzhen; Ding, Yu; Jia, Liyi; Karantza, Vassiliki; Tryfonidis, Konstantinos; Bardia, Aditya
Symptomatic Pneumonitis With Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC

不可切除的III期NSCLC同步放化疗后Durvalumab的症状性肺炎

JTO CLINICAL AND RESEARCH REPORTS
IF3.5
2024-03-013
OA
Vansteenkiste, Johan F.; Naidoo, Jarushka; Faivre-Finn, Corinne; Ozguroglu, Mustafa; Villegas, Augusto; Daniel, Davey; Murakami, Shuji; Hui, Rina; Lee, Ki Hyeong; Cho, Byoung Chul; Kubota, Kaoru; Broadhurst, Helen; Wadsworth, Catherine; Newton, Michael; Thiyagarajah, Piruntha; Antonia, Scott J.
A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies
ONCOIMMUNOLOGY
IF6.3
2023-12-208
OA
Lin, Chia-Chi; Garralda, Elena; Schoeffski, Patrick; Hong, David S.; Siu, Lillian L.; Martin, Miguel; Maur, Michela; Hui, Rina; Soo, Ross A.; Chiu, Joanne; Zhang, Tian; Ma, Brigette; Kyi, Chrisann; Tan, Daniel S. W.; Cassier, Philippe A.; Sarantopoulos, John; Weickhardt, Andrew; Carvajal, Richard D.; Spratlin, Jennifer; Esaki, Taito; Rolland, Frederic; Akerley, Wallace; Deschler-Baier, Barbara; Rispoli, Lawrence; Samant, Tanay S.; Chowdhury, Niladri Roy; Gusenleitner, Daniel; Kwak, Eunice L.; Askoxylakis, Vasileios; De Braud, Filippo
Phase III study of neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage triple-negative breast cancer (TNBC): KEYNOTE-522 Korean subgroup analysis
ANNALS OF ONCOLOGY
IF65.4
2023-11-010
PRE
Park, Y. H.; Im, S-A.; Ahn, J-H.; Kim, M. H.; Cortes, J.; Dent, R. A.; Pusztai, L.; McArthur, H. L.; Kummel, S.; Denkert, C.; O'Shaughnessy, J.; Mouret-Reynier, M-A.; Ferreira, M. I. R.; Cortes, M. Gion; Boileau, J-F.; Hui, R.; Zhu, Y.; Pan, W.; Karantza, V. V.; Schmid, P.

研究方向

暂未获取到该数据
E
Edward B. Garon
H 指数:76论文数:736被引数:5.5万
J
Javier Cortés
H 指数:113论文数:1,480被引数:6.7万
R
Rebecca Dent
H 指数:58论文数:320被引数:2.2万
L
LiuMark
H 指数:114论文数:1,397被引数:6.8万
C
Carsten Denkert
H 指数:116论文数:1,285被引数:6.9万
H
Heather L. McArthur
H 指数:43论文数:310被引数:9,958
E
Enriqueta Felip
H 指数:129论文数:1,499被引数:11.0万
D
Delvys Rodríguez‐Abreu
H 指数:57论文数:381被引数:4.7万
G
Gregory M. Lubiniecki
H 指数:32论文数:93被引数:3.2万
F
Fátima Cardoso
H 指数:103论文数:824被引数:6.5万